Verona Pharma plc

VRNA

Verona Pharma plc

VRNA

Insider Sentiment (TTM):

Last Purchase:2024-11-18Last Sale:2025-08-01Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2025-09-30Institutional Shares Owned:68,480,850Shares Outstanding:685,155,000Institutional Ownership Pct.:9.99%

Earnings Market Reaction:

Filing Date:N/APrice on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30
Assets
Cash And Cash Equivalents At Carrying Value	438	401	400	336	405	255	272	257	271	291	228	232
Accounts Receivable Net Current	83	62	31	7	-	-	0	-	-	-	-	-
Prepaid Expense Current	11	11	8	8	5	4	4	3	1	2	2	3
Assets Current
Assets Current	549	501	454	364	416	272	290	277	288	307	243	258
Inventory Net	9	7	6	4	-	-	0	-	-	-	-	-
Other Assets Current	4	13	3	3	3	2	3	6	6	2	3	3
Property Plant And Equipment Net	1	1	1	0	0	0	0	0	0	0	0	0
Inventory Noncurrent	6	7	2	-	-	-	0	-	-	-	-	-
Assets Noncurrent
Assets Noncurrent	24	25	21	18	18	18	18	16	16	16	16	16
Goodwill	1	1	1	1	1	1	1	1	1	1	1	1
Contract With Customer Asset Net Noncurrent	15	15	15	15	15	15	15	15	15	15	15	15
Operating Lease Right Of Use Asset	2	2	2	2	2	3	3	0	1	1	1	1
Assets	573	526	474	382	434	290	308	292	304	323	259	275
Liabilities And Stockhold…
Accounts Payable Current	3	9	11	7	4	5	3	1	2	7	3	8
Accrued Liabilities Current	43	32	17	18	20	8	4	7	7	18	14	23
Accrued Royalties Current And Noncurrent	3	4	1	-	-	-	0	-	-	-	-	-
Liabilities Current
Contract With Customer Liability Current	-	0	1	0	21	-	0	-	-	-	-	-
Liabilities Current	51	57	43	28	48	15	9	9	11	27	19	32
Operating Lease Liability Current	1	1	1	1	1	1	1	0	1	1	1	1
Taxes Payable Current	0	9	9	1	1	-	0	0	0	0	0	0
Other Liabilities Current	0	1	3	1	1	1	0	0	0	1	1	0
Long Term Debt Noncurrent	242	242	120	120	120	49	48	20	20	20	10	5
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	-	-	105	-	-	-	0	-	-	-	-	-
Liabilities Noncurrent	243	243	227	223	218	50	50	20	20	20	10	5
Operating Lease Liability Noncurrent	1	1	1	1	1	2	2	0	0	0	0	0
Liabilities	295	299	270	251	266	65	59	29	31	46	29	37
Common Stock Value	45	45	45	43	43	43	43	42	42	42	41	39
Additional Paid In Capital	806	766	728	622	617	602	601	601	596	591	529	526
Stockholders Equity
Stockholders Equity	278	227	205	130	168	225	249	264	273	277	230	237
Treasury Stock Value	-1	-1	-2	-1	-1	-1	-2	-1	-1	-1	-2	-0
Accumulated Other Comprehensive Income Loss Net Of…	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Retained Earnings Accumulated Deficit	-567	-579	-562	-528	-485	-414	-388	-374	-359	-350	-333	-322
Liabilities And Stockholders Equity	573	526	474	382	434	290	308	292	304	323	259	275
Common Stock Par Or Stated Value Per Share	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Common Stock Shares Issued	703	703	703	668	668	668	668	652	652	652	631	608
Shares Outstanding	688	681	-	655	649	647	644	640	636	632	606	602

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

No price variance data available.

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30
Liquidity Ratios
Current Ratio	10.71	8.86	10.63	13.03	8.61	18.40	33.33	30.68	26.29	11.57	12.77	8.04
Quick Ratio	10.32	8.53	10.30	12.59	8.50	18.15	32.91	30.31	26.21	11.51	12.64	7.94
Working Capital	497.61M	444.48M	410.89M	336.30M	367.95M	257.07M	281.02M	267.52M	276.88M	280.37M	223.97M	226.33M
Leverage & Debt
Debt to Equity	1.06	1.32	1.32	1.93	1.58	0.29	0.24	0.11	0.11	0.17	0.13	0.16
Interest Coverage TTM	-2.08	-6.31	-11.69	-11.22	-30.00	-21.66	-32.85	-38.18	-45.21	-99.84	-145.39	-237.15
Debt Ratio	0.51	0.57	0.57	0.66	0.61	0.22	0.19	0.10	0.10	0.14	0.11	0.14
Efficiency & Turnover
Asset Turnover TTM	0.44	0.29	0.11	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	136.43	191.40	271.91	448.07	-	-	-	-	-	-	-	-
Receivables Turnover TTM	2.68	1.91	1.34	0.81	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.11	-0.24	-0.27	-0.24	-0.19	-0.10	-0.09	-0.08	-0.08	-0.10	-0.13	-0.15
Free Cash Flow Per Share TTM	-0.11	-0.18	-0.19	-0.16	-0.08	-0.09	-0.08	-0.07	-0.08	-0.08	-0.11	-0.13
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-25.27%	-116.21%	-365.73%	-2,762.84%	-	-	-	-13,869.87%	-13,611.57%	-15,913.54%	-16,539.30%	-
Net Profit Margin TTM	-36.62%	-138.31%	-410.18%	-2,733.34%	-	-	-	-11,067.25%	-11,276.86%	-13,232.97%	-15,000.22%	-
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	1,127.95%	-100.00%	-100.00%	-100.00%	-	-98.86%	-98.86%	-98.86%	-100.00%
Net Income Growth (1Y)	-35.28%	158.50%	218.96%	203.27%	142.89%	4.64%	-20.86%	-37.82%	-5.78%	2.52%	23.63%	152.30%
EPS Growth (1Y)	-38.77%	145.68%	210.08%	196.90%	137.74%	0.71%	-33.97%	-46.98%	-28.01%	-20.49%	10.57%	120.40%
Calculated Values
Free Cash Flow TTM	-73.65M	-121.34M	-122.87M	-103.81M	-53.89M	-58.07M	-50.22M	-47.62M	-52.98M	-51.22M	-59.95M	-69.50M
Net Debt	-195.58M	-159.67M	-279.42M	-216.03M	-284.91M	-206.34M	-223.40M	-237.46M	-250.87M	-271.61M	-218.06M	-226.67M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-08-01Sale

Owner: Ebsworth, David R

Title: -

Shares: 1,904

Price/Share: $13.14

Value: $25,018.56

Shares Owned: 880,499

Relationship: Director

Ownership: Direct

2025-08-01Sale

Owner: Sinha, Vikas

Title: -

Shares: 4,328

Price/Share: $13.14

Value: $56,869.92

Shares Owned: 94,112

Relationship: Director

Ownership: Direct

2025-08-01Sale

Owner: Cunningham, Kenneth

Title: -

Shares: 10,808

Price/Share: $13.14

Value: $142,017.12

Shares Owned: 79,776

Relationship: Director

Ownership: Direct

2025-08-01Sale

Owner: Rickard, Kathleen A.

Title: Chief Medical Officer

Shares: 58,336

Price/Share: $13.14

Value: $766,535.04

Shares Owned: 2,607,472

Relationship: Officer

Ownership: Direct

2025-08-01Sale

Owner: Austwick, Michael

Title: -

Shares: 11,288

Price/Share: $13.14

Value: $148,324.32

Shares Owned: 12,712

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-08-01	Ebsworth, David R	Director	-	Direct	Sale	1,904	13.14	$25,018.56	880,499	4
2025-08-01	Sinha, Vikas	Director	-	Direct	Sale	4,328	13.14	$56,869.92	94,112	4
2025-08-01	Cunningham, Kenneth	Director	-	Direct	Sale	10,808	13.14	$142,017.12	79,776	4
2025-08-01	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	58,336	13.14	$766,535.04	2,607,472	4
2025-08-01	Austwick, Michael	Director	-	Direct	Sale	11,288	13.14	$148,324.32	12,712	4
2025-08-01	Ackermann, Christina	Director	-	Direct	Sale	1,808	13.14	$23,757.12	64,072	4
2025-08-01	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	208,912	13.14	$2,745,103.68	12,464,968	4
2025-08-01	Fisher, Andrew	Officer	General Counsel	Direct	Sale	9,584	13.14	$125,933.76	417,903	4
2025-08-01	Edwards, Martin	Director	-	Direct	Sale	10,808	13.14	$142,017.12	157,992	4
2025-08-01	Brady, James Aloysius	Director	-	Direct	Sale	824	13.14	$10,827.36	23,176	4
2025-08-01	Shah, Mahendra	Director	-	Direct	Sale	3,608	13.14	$47,409.12	93,472	4
2025-08-01	Deschamps, Lisa	Director	-	Direct	Sale	9,464	13.14	$124,356.96	84,856	4
2025-08-01	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	208,912	13.14	$2,745,103.68	13,376,144	4
2025-06-16	Fisher, Andrew	Officer	General Counsel	Direct	Sale	80,000	11.53	$922,400.00	359,999	4
2025-06-11	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	400,000	11.40	$4,560,000.00	13,190,168	4
2025-06-11	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	400,000	11.40	$4,560,000.00	12,278,992	4
2025-05-29	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	208,696	9.33	$1,947,133.68	13,590,168	4
2025-05-29	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	204,864	9.33	$1,911,381.12	12,678,992	4
2025-05-20	Sinha, Vikas	Director	-	Direct	Sale	160,000	9.39	$1,502,400.00	74,440	4
2025-05-15	Fisher, Andrew	Officer	General Counsel	Direct	Sale	80,000	8.57	$685,600.00	359,999	4
2025-05-14	Ackermann, Christina	Director	-	Direct	Sale	40,000	8.44	$337,600.00	41,880	4
2025-05-06	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	114,984	8.82	$1,014,158.88	2,546,472	4
2025-05-02	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	400,000	9.09	$3,636,000.00	13,990,168	4
2025-05-02	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	400,000	9.09	$3,636,000.00	13,078,992	4
2025-05-01	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	49,200	8.95	$440,340.00	2,633,320	4
2025-04-29	Sinha, Vikas	Director	-	Direct	Sale	160,000	8.92	$1,427,200.00	74,440	4/A
2025-04-29	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	90,360	8.98	$811,432.80	13,466,000	4
2025-04-29	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	34,384	8.98	$308,768.32	2,660,656	4
2025-04-29	Fisher, Andrew	Officer	General Counsel	Direct	Sale	26,072	8.98	$234,126.56	359,993	4
2025-04-29	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	90,360	8.98	$811,432.80	14,377,176	4
2025-03-12	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	79,264	8.35	$661,854.40	2,608,976	4
2024-12-06	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	162,800	5.01	$815,628.00	14,204,752	4
2024-12-06	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	183,728	5.01	$920,477.28	13,293,736	4
2024-12-02	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	1,600	5.00	$8,000.00	14,175,696	4
2024-12-02	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	3,200	5.00	$16,000.00	15,075,424	4
2024-11-25	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	1,600	5.00	$8,000.00	15,200,752	4
2024-11-25	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	240,000	4.90	$1,176,000.00	2,671,480	4
2024-11-25	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	1,600	5.00	$8,000.00	14,289,736	4
2024-11-18	Ebsworth, David R	Director	-	Direct	Purchase	20,000	4.44	$88,800.00	940,003	4
2024-11-11	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	2,400	5.00	$12,000.00	15,202,352	4
2024-11-11	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	2,400	5.00	$12,000.00	14,291,336	4
2024-11-06	Ackermann, Christina	Director	-	Direct	Purchase	41,880	4.74	$198,511.20	41,880	4
2024-11-06	Ebsworth, David R	Director	-	Direct	Purchase	39,360	4.80	$188,928.00	920,003	4
2024-11-04	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	80,784	4.39	$354,641.76	14,293,736	4
2024-11-04	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	94,144	4.39	$413,292.16	15,204,752	4
2024-10-25	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	4,800	4.38	$21,024.00	14,591,736	4
2024-10-25	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	3,200	4.38	$14,016.00	13,669,360	4
2024-10-22	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	159,344	4.38	$697,926.72	13,813,920	4
2024-10-22	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	157,912	4.39	$693,233.68	14,736,552	4
2024-09-11	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	600,000	3.76	$2,256,000.00	15,250,704	4
2024-09-11	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	600,000	3.76	$2,256,000.00	14,339,688	4
2024-08-13	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	398,400	3.22	$1,282,848.00	15,850,704	4
2024-08-13	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	398,400	3.22	$1,282,848.00	14,939,688	4
2024-08-12	Ebsworth, David R	Director	-	Direct	Purchase	36,000	2.87	$103,320.00	880,643	4
2024-05-03	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	36,248	1.96	$71,046.08	2,621,552	4
2024-02-05	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	36,248	2.22	$80,470.56	2,731,624	4
2023-11-20	Edwards, Martin	Director	-	Direct	Purchase	33,736	1.84	$62,074.24	144,800	4
2023-11-06	Ebsworth, David R	Director	-	Direct	Purchase	160,000	1.98	$316,800.00	844,643	4
2023-11-03	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	58,752	1.92	$112,803.84	2,840,640	4
2023-08-07	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	8,616	2.47	$21,281.52	15,521,248	4
2023-08-07	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	8,616	2.47	$21,281.52	16,431,800	4
2023-08-07	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	1,600	2.47	$3,952.00	2,872,528	4
2023-08-07	Poll, Claire	Officer	General Counsel	Direct	Sale	1,512	2.47	$3,734.64	1,907,367	4
2023-08-02	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	73,704	2.59	$190,893.36	16,707,688	4
2023-08-02	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	73,704	2.59	$190,893.36	15,797,136	4
2023-08-02	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	13,728	2.59	$35,555.52	2,952,672	4
2023-08-02	Poll, Claire	Officer	General Counsel	Direct	Sale	12,944	2.59	$33,524.96	1,955,839	4
2023-05-15	Orbimed, Advisors Llc, Or…	Director	-	Indirect	Sale	359,713	20.98	$7,546,778.74	3,777,778	4
2023-05-15	Gupta, Rishi	Director	-	Indirect	Sale	359,713	20.98	$7,546,778.74	3,777,778	4
2023-05-03	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	28,752	2.65	$76,192.80	2,971,136	4
2023-05-01	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	455,528	2.58	$1,175,262.24	15,976,784	4
2023-05-01	Poll, Claire	Officer	General Counsel	Direct	Sale	80,376	2.58	$207,370.08	1,979,063	4
2023-05-01	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	455,536	2.58	$1,175,282.88	16,887,336	4
2023-02-02	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	28,752	2.53	$72,742.56	3,077,312	4
2023-02-01	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	432,928	2.56	$1,108,295.68	17,342,872	4
2023-02-01	Poll, Claire	Officer	General Counsel	Indirect	Sale	152,000	2.59	$393,680.00	774,256	4
2023-02-01	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	413,168	2.56	$1,057,710.08	16,432,312	4
2022-12-23	Gupta, Rishi	Director	-	Indirect	Sale	2,170,368	23.20	$50,352,537.60	34,085,528	4
2022-12-23	Orbimed, Capital Gp Vi Ll…	Director	-	Indirect	Sale	2,170,368	23.20	$50,352,537.60	34,085,528	4
2022-12-22	Poll, Claire	Officer	General Counsel	Indirect	Sale	240,000	2.69	$645,600.00	774,256	4
2022-12-20	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	600,000	2.12	$1,272,000.00	17,775,800	4
2022-12-20	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	600,000	2.12	$1,272,000.00	16,845,480	4
2022-11-01	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	28,752	1.64	$47,153.28	3,091,024	4
2022-11-01	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	32,904	1.67	$54,949.68	18,375,800	4
2022-11-01	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	13,160	1.67	$21,977.20	17,445,480	4
2022-08-15	Blavatnik, Len, Ai Biotec…	TenPercentOwner	-	Indirect	Purchase	4,800,000	1.31	$6,288,000.00	55,911,648	4
2022-08-09	Zaccardelli, David	Director,Officer	President and CEO	Direct	Sale	600,000	1.75	$1,050,000.00	15,263,560	4
2022-08-09	Hahn, Mark W	Officer	Chief Financial Officer	Direct	Sale	600,000	1.75	$1,050,000.00	14,313,496	4
2022-08-02	Rickard, Kathleen A.	Officer	Chief Medical Officer	Direct	Sale	28,752	0.70	$20,126.40	2,376,040	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-09-30

9.99%

Inst. Shares: 68,480,850

Shares Outstanding: 685,155,000

2025-06-30

10.37%

Inst. Shares: 71,025,167

Shares Outstanding: 685,155,000

2025-03-31

9.72%

Inst. Shares: 66,060,593

Shares Outstanding: 679,405,000

2024-12-31

14.68%

Inst. Shares: 95,777,570

Shares Outstanding: 652,310,582

2024-09-30

9.60%

Inst. Shares: 62,577,719

Shares Outstanding: 651,944,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-09-30	68,480,850	685,155,000	9.99%
2025-06-30	71,025,167	685,155,000	10.37%
2025-03-31	66,060,593	679,405,000	9.72%
2024-12-31	95,777,570	652,310,582	14.68%
2024-09-30	62,577,719	651,944,000	9.60%
2024-06-30	62,988,707	648,217,000	9.72%
2024-03-31	64,891,524	645,701,000	10.05%
2023-12-31	65,319,500	634,142,660	10.30%
2023-09-30	63,185,708	638,239,000	9.90%
2023-06-30	60,972,410	634,469,000	9.61%
2023-03-31	58,298,962	621,451,000	9.38%
2022-12-31	45,212,440	529,071,526	8.55%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Verona Pharma plc (VRNA) — SEC Financial Statements & Analysis

Verona Pharma plc (VRNA) is a pharmaceutical preparations company, incorporated in X0. Verona Pharma plc trades on None as: VRNA. Based on its latest SEC filing (Form 10-Q, period ending 2025-06-30), Verona Pharma plc reported a 1127.95% year-over-year revenue growth, a Debt-to-Equity ratio of 1.06x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 1127.95%
Debt To Equity: 1.06x

Data as of 2025-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Verona Pharma plc in?

Verona Pharma plc (VRNA) operates in the Pharmaceutical Preparations industry.

What exchange does VRNA trade on?

Verona Pharma plc (VRNA) trades on the None.

Where is Verona Pharma plc incorporated?

Verona Pharma plc is incorporated in United Kingdom.